Detalhe da pesquisa
1.
A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer.
Invest New Drugs
; 39(6): 1613-1623, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34264412
2.
Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma.
Invest New Drugs
; 39(4): 1081-1088, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33660194
3.
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma.
Genome Res
; 23(9): 1422-33, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23788652
4.
A P-loop mutation in Gα subunits prevents transition to the active state: implications for G-protein signaling in fungal pathogenesis.
PLoS Pathog
; 8(2): e1002553, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22383884
5.
Somatic mutations in GRM1 in cancer alter metabotropic glutamate receptor 1 intracellular localization and signaling.
Mol Pharmacol
; 83(4): 770-80, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23303475
6.
Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.
Clin Cancer Res
; 29(17): 3438-3456, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37406085
7.
A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer.
Mol Cancer Ther
; 19(2): 460-467, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31645440
8.
A role for Regulator of G protein Signaling-12 (RGS12) in the balance between myoblast proliferation and differentiation.
PLoS One
; 14(8): e0216167, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31408461
9.
Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients.
Sci Rep
; 9(1): 15365, 2019 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-31653970
10.
Correction: Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.
Clin Cancer Res
; 30(9): 1992, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38690594
11.
A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.
Cancer Chemother Pharmacol
; 82(3): 407-418, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29926131
12.
Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.
Cancer Chemother Pharmacol
; 82(3): 419, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30014222
13.
Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.
Oncotarget
; 9(17): 13796-13806, 2018 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29568395
14.
Somatic mutations in CCK2R alter receptor activity that promote oncogenic phenotypes.
Mol Cancer Res
; 10(6): 739-49, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22516348
15.
Regulator of G-protein signaling 14 (RGS14) is a selective H-Ras effector.
PLoS One
; 4(3): e4884, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19319189
16.
A sweet cycle for Arabidopsis G-proteins: Recent discoveries and controversies in plant G-protein signal transduction.
Plant Signal Behav
; 3(12): 1067-76, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19513240
17.
A point mutation to Galphai selectively blocks GoLoco motif binding: direct evidence for Galpha.GoLoco complexes in mitotic spindle dynamics.
J Biol Chem
; 283(52): 36698-710, 2008 Dec 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-18984596
18.
Selective role for RGS12 as a Ras/Raf/MEK scaffold in nerve growth factor-mediated differentiation.
EMBO J
; 26(8): 2029-40, 2007 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-17380122